

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **ESSEX BIO-TECHNOLOGY LIMITED**

**億勝生物科技有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 1061)**

### **ANNOUNCEMENT**

#### **OBTAINING OF A CERTIFICATE OF GOOD MANUFACTURING PRACTICES FOR HUMAN DRUGS BY A WHOLLY-OWED SUBSIDIARY**

This announcement is made pursuant to Rule 13.09 of the Listing Rules and the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong).

On 23 December 2013, Zhuhai Essex was granted a GMP Drugs Certificate by 國家食品藥品監督管理局 (China Food and Drug Administration) for a period from 23 December 2013 to 22 December 2018 in respect of the Approved Products.

This announcement is made pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (“**Listing Rules**”) and the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong).

On 23 December 2013, 珠海億勝生物製藥有限公司 (Zhuhai Essex Bio-Pharmaceutical Company Limited\*) (“**Zhuhai Essex**”), an indirect wholly-owned subsidiary of Essex Bio-Technology Limited (the “**Company**”, and together with its subsidiaries referred to as the “**Group**”) of its new factory address located at 中國廣東省珠海市高新區科技六路88號 (No. 88, Keji 6th Road, Hi-Tech Zone, Zhuhai, Guangdong, China), was granted a 藥品GMP證書 (Certificate of Good Manufacturing Practice for Drugs) (the “**GMP Drugs Certificate**”) by 國家食品藥品監督管理局 (China Food and Drug Administration) for a period from 23 December 2013 to 22 December 2018 in respect of the following approved scope of products (“**Approved Products**”):

“重組牛碱性成纖維細胞生長因子滴眼液 (眼用制劑) (Recombinant Bovine Basic Fibroblast Growth Factor Eye Drops), 重組牛碱性成纖維細胞生長因子眼用凝膠 (眼用制劑) (Recombinant Bovine Basic Fibroblast Growth Factor Eye-Gel), 重組牛碱性成纖維細胞生長因子凝膠 (凝膠劑) (Recombinant Bovine Basic Fibroblast Growth Factor Gel)”

Zhuhai Essex is principally engaged in the manufacturing and selling of biopharmaceutical products. Since the obtaining of the GMP Drugs Certificate by its new factory located at 中國廣東省珠海市高新區科技六路88號 (No. 88, Keji 6th Road, Hi-Tech Zone, Zhuhai, Guangdong, China), the new factory will commence operation with immediate effect and the old factory of Zhuhai Essex located at 中國廣東省珠海市明珠北路63號東大電子城03棟 (Building 03, Dongda Electronic City, North Mingzhu Road #63, Zhuhai, China) will cease operation in January 2014.

With the compliance of the new Good Manufacturing Practice guidelines (2010 version), the GMP Drugs Certificate was issued under the newly completed factory that exhibits state-of-the-art technology and know-how in our manufacturing capability and expanded capacity, which underpins future growth potential for the Group in many years to come. This certification comes in timely and marks a good head start for the Group in 2014.

By order of the Board  
**Essex Bio-Technology Limited**  
**Ngiam Mia Je Patrick**  
*Chairman*

Hong Kong, 31 December 2013

*Executive directors of the Company as at the date of this announcement are Mr Ngiam Mia Je Patrick, Mr Fang Haizhou and Mr Zhong Sheng. Independent non-executive directors of the Company as at the date of this announcement are Mr Fung Chi Ying, Mr Mauffrey Benoit Jean Marie and Ms Yeow Mee Mooi.*

\* denotes an English translation of a Chinese name